US Pharma MarketingHIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir - Pharmaceutical Technology
Though yet to be finalised, the initial recommendation would mean the injectable PrEP would not be covered on the NHS. Though yet to be finalised, the initial recommendation would mean the injectable PrEP would not be covered on the NHS. Yeytuo’s approvals last year have been hailed as a momentous step for HIV prevention. Credit: Melnikov Dmitriy/Shutterstock.com. The National Institute for Health and Care Excellence (NICE) has recommended against reimbursement for Gilead’s twice-a-year PrEP medication lenacapavir, prompting a rebuttal from several HIV charities in the UK. An evaluation committee at the watchdog said that the drug should not be used…
Though yet to be finalised, the initial recommendation would mean the injectable PrEP would not be covered on the NHS.
Source: Pharmaceutical Technology